Patriot Green Energy Technology

Patriot Green Energy Technology Co., Ltd. is a Taiwan-based biotechnology company that specializes in the development and commercialization of botanical drugs. Despite its name, the company's primary focus is the life sciences sector, particularly in oncology supportive care and inflammatory disease treatments. Its lead product, PG2, is a purified botanical extract from Astragalus membranaceus and was the first botanical drug to receive approval from the Taiwan Food and Drug Administration for the treatment of cancer-related fatigue. The company operates as part of a strategic alliance with PhytoHealth Corp to advance botanical drug research using modern pharmaceutical standards. Patriot Green Energy Technology is publicly listed on the Taipei Exchange and continues to explore new therapeutic applications for its proprietary extraction technologies.